Satsuma Pharmaceuticals, Inc. filed its 10-K on Mar 28, 2023 for the period ending Dec 31, 2022. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Satsuma Pharmaceuticals, Inc.
Equities
STSA
US80405P1075
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.01% | 22.18B | |
-16.67% | 21.2B | |
-9.70% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |